Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry ... Read More
Alcon acquires Aerie Pharmaceuticals to expand eye care business
Alcon, an American Swiss medical company specializing in eye care products, has closed the previously announced $930 million acquisition of Aerie Pharmaceuticals, a NASDAQ-based pharmaceutical ... Read More